000132501 001__ 132501
000132501 005__ 20240229105020.0
000132501 0247_ $$2doi$$a10.3324/haematol.2017.176073
000132501 0247_ $$2pmid$$apmid:29217779
000132501 0247_ $$2pmc$$apmc:PMC5792278
000132501 0247_ $$2ISSN$$a0390-6078
000132501 0247_ $$2ISSN$$a1592-8721
000132501 0247_ $$2altmetric$$aaltmetric:30338740
000132501 037__ $$aDKFZ-2018-00188
000132501 041__ $$aeng
000132501 082__ $$a610
000132501 1001_ $$0P:(DE-He78)9dce98b15cdeea0377ee6c204ee5373e$$aMosebach, Jennifer$$b0$$eFirst author
000132501 245__ $$aPrognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.
000132501 260__ $$aPavia$$bFerrata Storti Foundation$$c2018
000132501 3367_ $$2DRIVER$$aarticle
000132501 3367_ $$2DataCite$$aOutput Types/Journal article
000132501 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1680684381_11715
000132501 3367_ $$2BibTeX$$aARTICLE
000132501 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132501 3367_ $$00$$2EndNote$$aJournal Article
000132501 520__ $$aAllogeneic stem cell transplantation is a therapeutic option under dispute but nonetheless chosen with increasing frequency for patients suffering from multiple myeloma in Europe. To study possible predictors of survival, 79 patients were investigated using whole-body magnetic resonance imaging to assess the visible tumor burden before and after allogeneic stem cell transplantation. Statistical analysis of clinical and imaging parameters included Cox regression models and distribution of survival time estimates (Kaplan-Meier method). Log rank test was used to determine the prognostic impact of the presence of focal lesions on survival. A higher tumor burden according to the lesion count was associated with a shorter overall survival (univariable/multivariable Cox regression: 1stmagnetic resonance imagingP=0.028/P=0.048; 2ndmagnetic resonance imagingP=0.008/P=0.024). Focal infiltration pattern itself seemed to be an additional adverse prognostic factor for overall survival (2ndMRIP=0.048), although no definite cut-off could be defined. Kaplan-Meier estimates at 60 months of follow up show a significant difference (Log rankP=0.04) for overall survival rates between patients with focal infiltration (32%) and those without (75%). Since this subgroup of patients may benefit from maintenance therapy, adoptive immunotherapy, or local interventions, whole-body imaging is an appropriate and highly recommendable diagnostic approach for detection of prognostically relevant lesions before and after treatment.
000132501 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000132501 588__ $$aDataset connected to CrossRef, PubMed,
000132501 7001_ $$aShah, Sofia$$b1
000132501 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b2
000132501 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3
000132501 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, Hartmut$$b4
000132501 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b5
000132501 7001_ $$aSchönland, Stefan$$b6
000132501 7001_ $$aHegenbart, Ute$$b7
000132501 7001_ $$0P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aHillengass, Jens$$b8
000132501 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2017.176073$$gVol. 103, no. 2, p. 336 - 343$$n2$$p336 - 343$$tHaematologica$$v103$$x1592-8721$$y2018
000132501 909CO $$ooai:inrepo02.dkfz.de:132501$$pVDB
000132501 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9dce98b15cdeea0377ee6c204ee5373e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132501 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132501 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132501 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aExternal Institute$$b4$$kExtern
000132501 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132501 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5$$aExternal Institute$$b8$$kExtern
000132501 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000132501 9141_ $$y2018
000132501 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132501 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132501 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132501 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132501 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132501 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000132501 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132501 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132501 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132501 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132501 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132501 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132501 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132501 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000132501 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000132501 980__ $$ajournal
000132501 980__ $$aVDB
000132501 980__ $$aI:(DE-He78)E010-20160331
000132501 980__ $$aI:(DE-He78)C060-20160331
000132501 980__ $$aUNRESTRICTED